rawfin.tv
Apellis Director Divests Stake Following Biogen Merger
MarketsstocksAI Generated

Apellis Director Divests Stake Following Biogen Merger

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Apellis Pharmaceuticals director Craig A. Wheeler has fully divested his stake in the company. This transaction occurred as part of the company's merger with Biogen.

APLSBIIBInsider TradingMergers & AcquisitionsCorporate Governance

Related Articles

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

stocks
EQT to Acquire Cleanaway Waste for $6.5 Billion

EQT to Acquire Cleanaway Waste for $6.5 Billion

stocks
S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

stocks
US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

stocks